mRNA 3139
Alternative Names: mRNA-3139Latest Information Update: 31 Mar 2023
At a glance
- Originator Moderna Therapeutics
- Class RNA
- Mechanism of Action Ornithine carbamoyltransferase expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Ornithine carbamoyltransferase deficiency disease
Most Recent Events
- 23 Feb 2023 mRNA 3139 is available for licensing as of 23 Feb 2023. https://www.modernatx.com/
- 22 Feb 2023 Preclinical trials in Ornithine carbamoyltransferase deficiency disease in USA (unspecified route, Injection) (Moderna Therapeutics pipeline, February 2023)